These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39130906)

  • 21. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease psychosis: presentation, diagnosis and management.
    Schneider RB; Iourinets J; Richard IH
    Neurodegener Dis Manag; 2017 Dec; 7(6):365-376. PubMed ID: 29160144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.
    Pagan FL; Schulz PE; Torres-Yaghi Y; Pontone GM
    CNS Drugs; 2024 May; 38(5):333-347. PubMed ID: 38587586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions.
    Heim B; Peball M; Krismer F; Djamshidian A; Seppi K
    Neuropsychiatr Dis Treat; 2023; 19():1303-1312. PubMed ID: 37274140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.
    Kitten AK; Hallowell SA; Saklad SR; Evoy KE
    Innov Clin Neurosci; 2018 Feb; 15(1-2):16-22. PubMed ID: 29497575
    [No Abstract]   [Full Text] [Related]  

  • 26. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
    Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
    J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Parkinson's Disease Psychosis.
    Elsibai H; Kualleny M; Fandy TE
    Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841
    [No Abstract]   [Full Text] [Related]  

  • 28. The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study.
    Evidente VGH; DeKarske D; Coate B; Abler V
    Ther Adv Neurol Disord; 2024; 17():17562864241228350. PubMed ID: 38476466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review.
    Stamenović J; Živadinović B; Đurić V
    J Chin Med Assoc; 2024 Aug; ():. PubMed ID: 39118220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
    Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
    Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
    Hermanowicz N
    CNS Spectr; 2018 Dec; 23(6):352-354. PubMed ID: 30588904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.
    Torres-Yaghi Y; Carwin A; Carolan J; Nakano S; Amjad F; Pagan F
    Neuropsychiatr Dis Treat; 2021; 17():3791-3818. PubMed ID: 34992373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
    Isaacson SH; Coate B; Norton J; Stankovic S
    J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
    Zahodne LB; Fernandez HH
    Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor Function Improvement After Electroconvulsive Therapy in a Parkinson's Disease Patient With Deep Brain Stimulator.
    Volkaerts L; Roels R; Bouckaert F
    J ECT; 2020 Mar; 36(1):66-68. PubMed ID: 31652177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
    Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
    J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
    [No Abstract]   [Full Text] [Related]  

  • 40. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
    Rajagopalan K; Rashid N; Kumar S; Doshi D
    J Med Econ; 2023; 26(1):34-42. PubMed ID: 36444507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.